AI-Enhanced Anti-Mycobacterial Therapy System

Publication ID: 24-11857521_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “AI-Enhanced Anti-Mycobacterial Therapy System,” Published Technical Disclosure No. 24-11857521_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857521_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,521.

Summary of the Inventive Concept

A novel system integrating oligo(carbamoylated guanidine)s (OCGs) with artificial intelligence (AI), Internet of Things (IoT), blockchain, and machine learning to create a personalized, adaptive, and secure anti-mycobacterial treatment platform.

Background and Problem Solved

The current TB treatment regimen is lengthy and rigorous due to difficulties associated with Mycobacterium tuberculosis (Mtb) resistance. The original patent introduced OCGs as a promising anti-mycobacterial agent, but its efficacy and treatment outcomes can be improved by integrating it with advanced technologies.

Detailed Description of the Inventive Concept

The AI-enhanced system comprises OCGs, AI for personalized medicine, IoT-enabled sensors for real-time monitoring, a blockchain-secured data storage system, and a machine learning algorithm for predicting mycobacterial resistance patterns. The AI optimizes OCG dosages based on patient-specific genomic data, while the IoT sensors track treatment efficacy and adjust dosages accordingly. The blockchain system ensures data integrity and utilizes novel, OCG-resistant materials for storing data. The machine learning algorithm predicts resistance patterns, enabling proactive treatment adjustments.

Novelty and Inventive Step

The new claims introduce a synergistic combination of OCGs with AI, IoT, blockchain, and machine learning, which is not obvious from the original patent. The integration of these distinct technologies creates a novel, more powerful system that addresses the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include using different AI algorithms, integrating with other IoT devices, or utilizing alternative blockchain platforms. Variations may include adapting the system for other infectious diseases or incorporating additional technologies, such as nanotechnology or gene editing.

Potential Commercial Applications and Market

The AI-enhanced anti-mycobacterial therapy system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in developing countries where TB is prevalent. The system's ability to provide personalized, adaptive, and secure treatment can improve treatment outcomes, reduce healthcare costs, and enhance patient quality of life.

CPC Classifications

Section	Class	Group
A	A61	A61K31/17
A	A61	A61K31/133
A	A61	A61K31/277
A	A61	A61K31/4409
A	A61	A61K31/47
A	A61	A61K31/496
A	A61	A61K31/498
A	A61	A61K31/4965
A	A61	A61K31/5377
A	A61	A61P31/06
C	C07	C07C279/12
C	C07	C07D295/215
C	C08	C08G65/00
C	C08	C08G71/02
C	C07	C07C2601/16

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical chemistry, specifically anti-mycobacterial drug development and personalized medicine technologies involving molecular design, drug delivery systems, and computational healthcare solutions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmaceutical chemistry, biotechnology, or biomedical engineering, possessing expertise in drug design, computational methods, and interdisciplinary technology integration

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies with existing pharmaceutical compounds represents a predictable extension of current drug development strategies. The combination of OCGs with AI, IoT, and machine learning follows established trends in personalized medicine and precision healthcare technologies. The technical elements disclosed in the PTD represent incremental improvements that leverage known computational techniques to enhance the utility of the source patent's molecular compounds.

Obvious Combinations & Variations

Source Patent Element

Oligo(carbamoylated guanidine) molecular structures for anti-mycobacterial treatment

PTD Variation

AI-driven personalized dosage optimization using patient genomic data

Obviousness Reasoning

Personalized medicine approaches are well-established, and applying computational methods to drug dosing represents a predictable solution for improving treatment efficacy

Source Patent Element

Pharmaceutical composition for treating tuberculosis

PTD Variation

IoT-enabled real-time monitoring of treatment response and dynamic dosage adjustment

Obviousness Reasoning

Remote patient monitoring and adaptive treatment protocols are known techniques in medical technology, representing an obvious technological progression

Source Patent Element

Anti-mycobacterial drug development targeting specific molecular pathways

PTD Variation

Machine learning algorithm for predicting mycobacterial resistance patterns

Obviousness Reasoning

Computational prediction of drug resistance is a standard approach in infectious disease management, utilizing established machine learning techniques

Source Patent Element

Pharmaceutical data management for clinical trials

PTD Variation

Blockchain-secured decentralized data storage system for treatment tracking

Obviousness Reasoning

Secure, decentralized data management is a known solution for maintaining clinical data integrity across healthcare technologies

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this Published Technical Disclosure would have been obvious to a Person Having Ordinary Skill In The Art at the time of invention, as they represent predictable combinations of known technologies with the molecular compounds described in US Patent 11857521, integrating standard computational methods with established pharmaceutical development strategies to enhance treatment methodologies.

Original Patent Information

Patent Number	US 11,857,521
Title	Anti-mycobacterial drugs
Assignee(s)	The Florida International University Board of Trustees